We looked at the pattern of gender representation of all solid tumor phase 3 clinical trials presented at the ASCO annual meeting over a decade. The reason we wanted to look at it is there has been previous research that showed that female authors are typically underrepresented in large phase three clinical trials. What we didn’t know is if there has been a change in the trend...
We looked at the pattern of gender representation of all solid tumor phase 3 clinical trials presented at the ASCO annual meeting over a decade. The reason we wanted to look at it is there has been previous research that showed that female authors are typically underrepresented in large phase three clinical trials. What we didn’t know is if there has been a change in the trend. So we looked at the pattern of female authorship over a period of 10 years. And what we found was that firstly, female authors were underrepresented. The proportion of female authors was 28% over the whole study period. But interestingly, we saw that female authorship is increasing more recently. But what’s more interesting is we saw that this increase has not been uniform. We saw more increase in senior authorship compared to first authorship. We also saw significant variation based on the tumor tract as well as the geographic region of the female authors.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
